NCT03596086View on ClinicalTrials.gov

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Glioblastoma MultiformeAstrocytoma, Grade III
Interventions
DRUG

ADV/HSV-tk (gene therapy)

The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy

Trial Locations (1)

77030

RECRUITING

Houston Methodist Neurological Institute, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

David Baskin MD

OTHER